

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

ORIGINAL ARTICLE

**SARS-CoV-2 vaccine and increased myocarditis mortality risk:
A population based comparative study in Japan**

AUTHORS

Sintaroo Watanabe, MD, PhD ¹
Rokuro Hama, MD ²

AUTHOR AFFILIAIONS

¹Japan Marine United Corporation, Kure Shipyard, Kure, Japan
<https://orcid.org/0000-0002-6189-7654>
²Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Osaka, Japan
<https://orcid.org/0000-0002-3802-6754>

Correspondence to: Rokuro Hama,

Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”,
Email: gec00724@nifty.com

KEYWORDS

Epidemiology, COVID-19, Drug-related side effects and adverse reactions

WORD COUNT

Abstract: 299 words
Main: 4 465 words
Tables and Figures: 4 + 2
Supplementary Tables and Figures: 6 + 2
References: 53

CONTRIBUTIONS: SW proposed to conduct the study, RH and SW designed the study. Both authors independently converted the pdf data disclosed by the Japanese government into excel files and confirmed data matched. Then data collection, classification, and analyses were done first by the SW and later confirmed by RH, with any discrepancies being discussed and decided by both parties. SW and RH contributed equally to this study and reviewed the final manuscript.

COMPETING INTERESTS: All authors have completed the ICMJE uniform disclose form available at <https://www.icmje.org/disclosure-of-interest/>, RH wrote a book entitled “Drugs to avoid,

1 and infectious diseases including COVID-19” published on 1 December 2020.

2

3 **FUNDING**

4 This survey does not receive any financial support from businesses or public institutions.

5

6 **ETHICAL APPROVAL**

7 This study was conducted based only on data disclosed by the Japanese government. Japanese law
8 and guidelines do not require an ethical approval for such research.

9

10 **DISCLAIMER**

11 The content is the personal view of the author and is not related to the official view of the authors'
12 organization.

13

1 **SUMMARY BOXES**

2

3 **ALREADY KNOWN ON THIS TOPIC**

4 There are many epidemiological studies showing increased myocarditis incidence after
5 SARS-CoV-2 vaccination. There are also some case reports of fulminant myocarditis after receiving
6 SARS-CoV-2 vaccine. However, no epidemiological studies focusing the association between
7 vaccination and myocarditis death.

8

9 **WHAT THIS STUDY ADDS**

10 Myocarditis mortality rate ratios (MMRRs) and their 95% confidence intervals (95% CIs) after
11 receiving SARS-CoV-2 vaccine compared with that in the reference population (previous 3 years)
12 were significantly higher not only in young adults (highest in the 30s with MMRR of 6.69) but also
13 in the elderly. Standardised mortality ratio (SMR) for myocarditis was 1.65 (1.07 to 2.55) for those
14 60 years or older and 2.01 (1.44 to 2.80) in overall age. The risk of myocarditis mortality in the
15 SARS-CoV-2 vaccinated population may be 4 times or higher than the apparent MMRRs
16 considering healthy vaccinee effect. Unreported post-vaccination deaths should also be considered
17 as suggested by the extremely high myocarditis mortality odds ratio (205.60; 133.52 to 311.94).

18

1 **ABSTRACT**

2 **Objective:** To investigate the association between SARS-CoV-2 vaccination and myocarditis death

3 **Design:** Population based comparative mortality study

4 **Setting:** Japan

5 **Participants:** Vaccinated population was 99 834 543 individuals aged 12 years and older who have
6 been received SARS-CoV-2 vaccine once or twice by 14 February 2022. Reference population was
7 defined persons aged 10 years and older from 2017 to 2019.

8 **Main outcome measures:** The primary outcome was myocarditis death, defined as the case with
9 "myocarditis" for cause of death and with onset 28 days or less after vaccination disclosed on 5
10 August 2022. Myocarditis mortality rate ratio (MMRR) of the SARS-CoV-2 vaccinated to the
11 reference population by 10-year age group and standardised mortality ratio (SMR) were calculated.
12 Mortality odds ratios (MORs) by 10-year age group were also calculated for supplementary analysis.
13 Healthy vaccine effect-adjusted MMRRs (adMMRRs) or adjusted SMR (adSMR) were calculated
14 by dividing MMRRs or SMR by 0.24 respectively.

15 **Results:** Number of myocarditis death which met the inclusion criteria were 38 cases. MMRR (95%
16 confidence interval) was 4.03 (0.77 to 13.60) in 20s, 6.69 (2.24 to 16.71) in 30s, 3.89 (1.48 to 8.64)
17 in 40s, respectively. SMR of myocarditis was 2.01 (1.44 to 2.80) for overall vaccinated population,
18 1.65 (1.07 to 2.55) for those 60 years or older. Estimated adMMRRs and adSMR were about 4 times
19 higher than the MMRRs and SMR. Pooled MOR for myocarditis were 205.60 (133.52 to 311.94).

20 **Conclusion:** SARS-CoV-2 vaccination was associated with higher risk of myocarditis death, not
21 only in young adults but also in all age groups including the elderly. Considering healthy vaccinee
22 effect, the risk may be 4 times or higher than the apparent risk of myocarditis death. Underreporting
23 should also be considered. Based on this study, risk of myocarditis following SARS-CoV-2
24 vaccination may be more serious than that reported previously.

25

1 INTRODUCTION

2 Amongst the several safety concerns of SARS-CoV-2 vaccination, myocarditis is one of the most
3 important adverse reactions which package insert warn as “Post marketing data demonstrate
4 increased risks of myocarditis and pericarditis”.^{1,2} After a notification of a possible link between
5 SARS-CoV-2 vaccination and myocarditis by the US Centers for Disease Control and Prevention
6 (CDC),³ a number of case reports have been published⁴ and several fatal cases have also been
7 published.⁵⁻¹² In Japan, a 27-year-old professional athlete with no history of symptomatic illness
8 except orthopedic problem was rushed to hospital with cardiac arrest on day eight of the first dose
9 of mRNA-1273 (Moderna) vaccine and subsequently died, with autopsy results revealing
10 myocarditis.¹² A non-comparative epidemiological study indicated that the highest incidence of
11 myocarditis was reported in male patients between the ages of 16 and 29 years.¹³ Comparative
12 epidemiological studies showed that SARS-CoV-2 vaccination is associated with increased risk of
13 myocarditis especially in adolescent and young adults without exception.¹⁴⁻¹⁸ However, they
14 reported that myocarditis after vaccination was mild^{14,16} and did not focus on the fatal cases.¹⁴⁻¹⁸
15 The package inserts of SARS-CoV-2 vaccine do not mention the possibility of death from
16 myocarditis after the vaccination.^{1,2} To our best knowledge, no epidemiological studies have
17 conducted to investigate the association of increased risk of SARS-CoV-2 vaccine on myocarditis
18 death.

19 The primary objective of this study is to investigate association between SARS-CoV-2 vaccine and
20 myocarditis deaths comparing mortality rate with general population, then to provide a new
21 discussion on the healthy vaccinee effect in using SARS-CoV-2 vaccine, especially on death. In
22 addition, all-cause death after vaccination was also investigated and under-reporting of deaths was
23 discussed.

24

25 METHODS

26 This study compared myocarditis mortality rate in the SARS-CoV-2 vaccinated with that in the
27 general population in Japan. The study was based on the materials and the vital statistics disclosed
28 by the Japanese government.

29

30 Data sources and case definition

31

32 1. Vaccinated population

33 The vaccinated population was defined as those who had received the first or the second doses of
34 SARS-CoV-2 vaccine since the start of the vaccination program (17 February 2021) until 14
35 February 2022. The number of persons received vaccine by number of doses was disclosed by the
36 Japanese Cabinet Office by 10-year age group without background information for sex, vaccine type
37 and others.¹⁹ According to this information, 99 834 543 persons received the first dose and 99 117
38 143 persons received the second dose. Of the Japanese population aged 12 years or older, 89.6%

1 received at least one dose of SARS-CoV-2 vaccine.

2 The number of vaccinated populations by number of doses, by vaccine type for all age groups
3 combined was also disclosed.²⁰ This information was used to estimate the interval between the first
4 and the second dose. The discrepancy between the total number of vaccinees by age group and the
5 total number of vaccinees by vaccine type may be due to the presence of vaccination cases of
6 unknown age group at the time of reporting.

7

8 **2. Death cases after receiving SARS-CoV-2 vaccine**

9 Data for the death cases after receiving SARS-CoV-2 vaccine were based on “the summary list of
10 death cases after SARS-CoV-2 vaccination” as pdf files that were disclosed by the panels of experts
11 on vaccination and adverse reactions under Japan’s MHLW at 5 August 2022.²¹⁻²³ Both authors
12 independently converted the pdf data into excel files and confirmed data matched. Total number of
13 death cases reported by 22 July and disclosed on 5 August was 1 797 (Fig 1).

14 In Japan, doctors are required to report serious adverse reactions to vaccine in general including
15 death within 28 days if they suspected an association with vaccination.²⁴ For SARS-CoV-2 vaccine,
16 those occurred during the period considered by a physician as highly relevant to vaccination were
17 required to report at the beginning of the vaccination program.²⁴ Subsequently, physicians were
18 required active consideration of reporting myocarditis, pericarditis and thrombosis occurring within
19 28 days after vaccination if they suspected an association with vaccination.²⁵ Therefore, we defined
20 the death cases for comparison of mortality rate as those in which the onset (start of signs and
21 symptoms leading to death) was known as occurred within 28 days after the last dose of
22 SARS-CoV-2 vaccine (reasons for inclusion of onset within 28 days are explained later in detail).
23 We restricted the vaccinee who received one or two dose and excluded those with third or fourth
24 dose to avoid further healthy vaccinee effect.^{26 27} Number of included death cases was 1 362 in total
25 (Fig 1).

26

27 **3. Myocarditis death after SARS-CoV-2 vaccination**

28 “Myocarditis death case” after vaccination was defined as the cases in which “myocarditis” was
29 described in the cause of death column of the above summary list, regardless of diagnostic method.
30 They were classified as death from I40 (acute myocarditis) under the 10th revision of the
31 International Statistical Classification of Diseases and Related Health Problems (ICD-10).

32 On the 5 August 2022 list, number of included myocarditis death reports was 38, of which 27 were
33 on the 18 February 2022 list and 11 new deaths were added since then.

34 Diagnostic bases for myocarditis are classified according to the information on the summary list of
35 death cases disclosed on 5 August 2022 as follows: 1. Autopsy and/or myocardial biopsy, 2.
36 Elevated Troponin with blood test, 3. Other blood test and/or (ECG and/or UCG), 4. Only symptoms.
37 Diagnostic basis for the lower number does not include the diagnostic basis for the higher number.

38

1 **4. Calculation of person-years of exposure for vaccinated population**

2 Average days from first to second dose are different among three products: 21 days for BNT162b,¹
3 28 days for mRNA-1273,² and 40 days for ChAdOx1 nCoV-19.^{28 29} The number of second dose
4 were 84 023 380 for BNT162b, 16 090 036 for mRNA-1273, and 58 300 for ChAdOx1 nCoV-19
5 (Table S1). However, the number of doses by age group and by vaccine type was not disclosed.
6 Therefore, weighted average days from first to second dose for overall ages was estimated as 22.14
7 days in overall ages (Table S2).

8 Based on the above information, the person-years of observation for the first dose and the second
9 dose were calculated as follows: $D = (A \times 22.14 + B \times 5.86) / 365$, $E = C \times 28 / 365$, $F = D + E$. where
10 22.14 is the weighted average days from the first dose to the second dose and 5.86 is 28 days of
11 observation period - 22.12, A is the number of vaccinees who received the first dose, B is that with
12 only the first dose, C is that with the second dose, D is the person-years for the first dose, E is for
13 the second dose and F is total person-years.

14 **5. Reference population and death**

15 We chose the general Japanese population during the period from 2017 through 2019 in the
16 pre-COVID-19 pandemic era as reference population and death for comparison based on the vital
17 statistics in 2017, 2018 and 2019.

18 Myocarditis mortality rates in the reference population were calculated from the total number of
19 myocarditis deaths by total population by 10-year age groups in three years from 2017 to 2019.³⁰⁻³⁵

20 **Outcome measures and statistical analyses**

21 Primary outcome measure was myocarditis mortality rate. We compared the observed mortality
22 rate of myocarditis with the expected mortality rate using data for reference population. Myocarditis
23 mortality rate ratios (MMRRs) and their 95% confidence intervals (95% CIs) by 10-year age group
24 were calculated.
25 were calculated.

26 Sensitivity analysis was performed as follows:

- 27 1) Standardised mortality ratio (SMR) for overall age stratified by 10-year age groups.
- 28 2) SMRs for 3 age groups (12-39, 40-59 and 60 or older) stratified by 10-year age groups.
- 29 3) SMR by the vaccination status after the first or second dose.
- 30 4) SMR for all-cause death.
- 31 5) Mortality odds ratio (MOR) by 10-year age group for myocarditis applying reporting odds ratio
32 (ROR).³⁶
- 33 6) MMRRs and SMR adjusted by the healthy vaccinee effect were estimated: Healthy vaccinee
34 effect by SARS-CoV-2 vaccination expressed as the rate ratio of mortality rate in vaccinated to that
35 in the reference general population was shown approximately as 0.10 to 0.24 (95% CI were not
36 given).^{26 27} An approximate healthy vaccinee effect-adjusted MMRRs (adMMRRs) or adjusted
37

1 SMR (adSMR) were yielded by dividing MMRRs or SMR by 0.10 to 0.24 respectively without 95%
2 CI.

3
4 The valid reasons for comparing myocarditis mortality rate of vaccinee with onset within 28 days
5 from the last dose and of the reference population are based on the following. In the reference
6 population, death cases in which signs and symptoms of myocarditis leading to death develop
7 during the observation period (From the beginning through the end of the year) and die after the
8 observation period are not included in the mortality calculation, whereas cases that develop before
9 the observation period and die during the observation period are included in the mortality
10 calculation (Fig S1a).

11 In the post-vaccination population, on the other hand, a case in which signs and symptoms of
12 myocarditis leading to death had already developed before vaccination would have never been
13 reported as a death case possibly or probably associated with vaccine and is never included in the
14 mortality analysis. Hence, cases in which signs and symptoms of myocarditis leading to death
15 develop during the observation period should be included in the mortality analysis among
16 vaccinated population for fair comparison with the reference population (Fig S1b).

17 Using the same method, number of all-cause deaths in the post-vaccinated population was
18 calculated and compared with the expected number of deaths from all-cause.

19 All statistical analyses were performed with Stats Direct (Version 3.3.5). The significance level
20 was set at $P < 0.05$. Statistical multiplicity was not tested because this is rather an exploratory study
21 but not a hypothesis confirming study.

22 Ethical approval was not obtained for this study because it was based on the disclosed data and is
23 not required to obtain ethics approval under Japanese law and guidelines.

24 25 **Patient and Public involvement**

26 Patients and public were not involved in the design, analyses, in this study because the research
27 agenda was urgent.

28 29 **RESULTS**

30 The number of included death cases for analysis is 1 362 including 38 myocarditis death and their
31 characteristics are shown in Table 1.

32 Persons who died from myocarditis death were younger, used more mRNA-1273 and occurred
33 more after the second dose than those from other causes after SARS-CoV-2 vaccination.
34 Myocarditis was diagnosed by autopsy and/or myocardial biopsy in half cases.

35 Table 2 shows the number of vaccinated persons by age and the person-years of observation
36 calculated from them. Table 3 shows the population, causes of death, and their crude mortality rates
37 for 2017-2019, used as reference. Details for each year are shown in the Table S3.

38

1 **Myocarditis mortality in SARS-CoV-2 vaccinated population compared with reference** 2 **population**

3 MMRs and their (95%CI) after receiving SARS-CoV-2 vaccine were as follows: 4.03 (0.77 to
4 13.60) in 20s, 6.69 (2.24 to 16.71) in 30s, and 3.89 (1.48 to 8.64) in 40s. Except 10s and 50s in
5 which myocarditis death was zero, each point estimates of the MMRR exceeded 1.0. SMR of
6 myocarditis was 2.01 (1.44 to 2.80) for overall vaccinated population, 1.63 (0.95 to 2.78) after the
7 first dose and 2.21 (1.45 to 3.37) after the second dose. Details were shown in Fig 2 and Table 4.
8 SMR of myocarditis in those aged 12-39, 40-59 and the elderly overall (60 years or older) was 4.06
9 (2.02 to 8.18), 1.83 (0.85 to 3.93) and 1.65 (1.07 to 2.55) respectively.

10

11 **All-cause mortality in SARS-CoV-2 vaccinated population**

12 The apparent rate ratios for all-cause death after receiving SARS-CoV-2 vaccine were shown in
13 Table S4. The apparent SMR for all-cause mortality was 0.01.

14

15 **Mortality odds ratio for myocarditis**

16 Age-stratified and pooled MORs for myocarditis death after receiving SARS-CoV-2 vaccine were
17 shown in Table S5. Except 10s and 50s in which reported myocarditis death were zero, point
18 estimates MORs for myocarditis were above 60. The pooled MOR (95% CI) for myocarditis death
19 was 205.60 (135.52 to 311.94).

20

21 **Healthy vaccinee effect adjusted MMRRs**

22 Estimated point adMMRRs were approximately 17 to 39 in 20s, 28 to 64 in 30s, 16 to 37 in 40s, 5
23 to 11 in 60s, more than 7 in 70s or older and adSMR was 9 to 19 in overall vaccinated population
24 (95%CI were not calculated).

25

26 **DISCUSSION**

27

28 **Principal findings**

29 Using the disclosed data by the Japanese government, we observed increased myocarditis mortality
30 rate ratio in the SARS-CoV-2 vaccinated population compared with general population during three
31 years pre-COVID-19 pandemic era, especially in young adults (MMRR: 6.69 in 30s). However, not
32 only in young adults, but also in the middle aged (40s) and in the elderly and overall vaccinated,
33 increased risk of myocarditis death is associated with vaccination even without consideration of
34 healthy vaccinee effect. The pooled MOR for myocarditis death was as high as 205.6. Very rough
35 estimation of healthy vaccinee effect adjusted MMRRs showed as high as 28 to 64 in 30s and about
36 9 to 19 for adSMR which were closer to pooled MOR. Increased risk was higher after the second
37 dose than the first dose as shown in previous epidemiologic studies focusing on hospitalised
38 myocarditis patients.¹⁴⁻¹⁸

1

2 **Strengths of our study**

3 This study has several strengths. First this is the first epidemiological study that show the
4 increased risk of myocarditis mortality after the SARS-CoV-2 vaccination. Previous
5 epidemiological studies which reported the increased risk of myocarditis did not report the
6 increased death from myocarditis¹⁴⁻¹⁸ with emphasis that most cases were mild,^{14 16} that deaths
7 were rare with no deaths of persons younger than 40 years¹⁷ and that one person died with
8 fulminant myocarditis in the nationwide Israeli study.¹⁴

9 One of the most important reasons for such disregard of fatal myocarditis may be due to the
10 differences in the population investigated between the present study and previous comparative
11 epidemiological studies. The largest vaccinated populations involved among the previous studies
12 are up to about 18 million vaccinees from England¹⁸ and Nordic 4 countries.¹⁷ Both populations are
13 less than one-fifth of vaccinee population of this study (about 100 million).

14 Mortality rate from myocarditis in England and Wales in 2017 to 2019 is about 30% lower than
15 that in Japan stratified by 10-year age group (relative risk: 0.71, 95%CI: 0.54 to 0.94, $P=0.018$, by
16 random effect, $I^2=43\%$) by our calculation. From these data, expected myocardial death in Patone's
17 vaccinee population in England is estimated at approximately 2.0 without vaccination.¹⁸ Hence it
18 may be very difficult to detect increased mortality, if vaccine is associated with increased risk of
19 myocarditis death. Moreover, it is difficult to assess risk of death by self-controlled case series
20 method that Patone et al¹⁸ used. It is also reasonable that there were no deaths among cases for
21 patients younger than 40 years in Karlstad's study¹⁷ and that one person died with fulminant
22 myocarditis in the nationwide Israeli study.¹⁴

23 Second, we showed that increased risk of myocarditis death was seen in all age groups even
24 without consideration of healthy vaccinee effect.

25 Third, we pointed out that if healthy vaccinee effect is considered, the risk of SARS-CoV-2
26 vaccine on myocarditis death may be much higher, with rate ratio up to 28 to 64 in 30s.

27 Fourth in addition, we showed that pooled MOR is extremely high although it is assumed that
28 reports of cases with myocarditis after SARS-CoV-2 vaccine may be enhanced because it was
29 widely reported in the media.

30 Fifth these results show that myocarditis mortality is increased in vaccinated persons and provide
31 important insights into the consideration of benefits and harms of the SARS-CoV-2 vaccine.

32

33 **Limitations of this study**

34 This study has several limitations. First, diagnosis of myocarditis death after SARS-CoV-2 vaccine
35 is based on the physician's diagnosis and is not based on exactly the newly proposed Brighton's
36 case definition.³⁷ However, 50 % of myocarditis cases were diagnosed by autopsy and/or
37 myocardial biopsy. They are exactly the level 1 myocarditis (definite case) by the Brighton's case
38 definition. Including above definite cases, almost 90% of cases were diagnosed at least blood test

1 and/or ECG and/or UCG. Cases based on symptoms only or unknown methods were 11%. Moreover,
2 diagnostic base of the myocarditis death in the reference general population in 2017 through 2019 is
3 not known and is also based on physician's diagnosis. Previous studies ¹⁴⁻¹⁸ supported a high
4 incidence of post- SARS-CoV-2 vaccination myocarditis, making it difficult to believe that
5 diagnostic accuracy is a factor in overestimating myocarditis mortality after vaccination.

6 Second, because myocarditis after SARS-CoV-2 vaccine received media attention, it is likely that
7 physicians paid more attention and reported more. It might be one of the reasons for extremely high
8 pooled MOR for myocarditis death. However, this may be resulted from underreporting of death
9 from other causes, because not all deaths after SARS-CoV-2 vaccine were reported. There is no
10 obligation to report all post-vaccination deaths, therefore only those cases where a physician
11 suspected association to vaccination are reported and disclose by the MHLW. In the United States
12 (US), 610 million doses of the SARS-CoV-2 vaccine had been administered until 31 August 2022,
13 and about 16 000 post-vaccination deaths had been reported, ³⁸ while in Japan, only about 1 500
14 post SARS-CoV-2 vaccination deaths had been disclosed against 200 million doses of the vaccine
15 until 14 February 2022. If post-vaccination deaths were reported on a par with the US, this could be
16 about 3.5 times higher. The apparent SMR for all-cause deaths were as low as 0.01. It is far lower
17 than those estimated by other data. For example, randomized control trials have shown that the
18 SARS-CoV-2 vaccine was not effective in reducing all-cause death. ^{39 40} The results of analysis ^{26 41}
19 using data from UK statistics ⁴² showed that age adjusted non-COVID-19 mortality rate in the ever
20 vaccinated compared with that in the general population was estimated at 0.61 in January 2021.
21 These results indicate that there was substantial underreporting of SARS-CoV-2 post-vaccination
22 deaths. Mevorach revealed that the risk of myocarditis morbidity after vaccination was highest
23 among second-time vaccinators aged 16-19 years. ¹⁴ On the other hand, Japan's MHLW database had
24 not yet listed any myocarditis deaths between the ages of 12 and 19 years. Subsequently,
25 vaccination of people aged 5-11 years began in Japan, and as of 5 August 2022, one person had died
26 from myocarditis. ⁴³

27 Third, SMR was only adjusted for age, MMRRs and SMRs were not adjusted for sex and for other
28 cofounding factors such as calendar period, health care worker status, nursing home resident, and
29 comorbidities that Husby et al ¹⁶ and/or Karlstad et al ¹⁷ adjusted. However, proportion of male
30 among patients died from myocarditis (65.8%) was not statistically significant as compared with
31 that among reference 3-year population (59.0%). Mevorah ¹⁴ discussed that although selection bias
32 in their study was possible, they considered it unlikely, since they used data from the entire nation.
33 At the end of the study period, proportion of vaccinated at least one dose was 59.0 % on 31 May
34 2021 for their study ¹⁴, 75.3 % on 7 Oct 2021 for Danish study ¹⁶ and 76.3 % on 15 December 2021
35 for UK study ¹⁸, while it was 81.6 % on 14 Feb 2022 in our study according to the Data on
36 COVID-19 by Our World in Data ⁴⁴ and 89.6 % among the age of 12 years or older (the
37 vaccine-indicated population) in Japan.
38 Mevorah et al ¹⁴ reported similar results as those adjusted for potential confounders other than age

1 and sex, although they were unable to adjust for them. Moreover, according to the results of
2 Mevorah's data analysis by us, most "adjusted" incidence rate ratios were higher than the "crude"
3 rate ratios. Hence, only adjustment for age and not for other potential cofounders may not affect the
4 results.

5 Forth, we could not compare relative risk among products, BNT162b2 (Pfizer-Biotech) or
6 mRNA-1273 (Moderna), because precise data for number of persons who received each product by
7 age group until the cut off day (14 February 2022) were not disclosed. However, according to the
8 analysis by National Institute of infectious diseases,⁴⁵ proportion of reports for myocarditis among
9 male 10s and 20s who received second dose of mRNA-1273 was 102.1 and 47.2 /million person
10 respectively, while 15.4 and 10.0 /million person for second dose of BNT162b2. If the distribution
11 of number of persons who received each product by age group at the cut off day (14 February 2022)
12 were the same as reported on 3 December 2021, mortality rate ratio from myocarditis among those
13 who were younger than 40 years and received mRNA-1273 compared with those who received
14 BNT162b2 show no significant increase: 3.12 (95%CI: 0.84 to 11.63, $P=0.073$), while it was not
15 significant among those 40 years or older.

16 Fifth, we have no evidence on healthy vaccinee effect of SARS-CoV-2 vaccine in Japan. However,
17 there are more than one evidence that indicates healthy vaccinee effect of SARS-CoV-2 vaccine in
18 the world. One^{26 41} is the results of analysis using data from UK statistics⁴² and the other^{27 41} is the
19 results of analysis using the published data in the peer review journal.^{46 47}

20 According to the former analysis, COVID-19-related mortality rate ratio (MRR) of those who died
21 21 days or more after the second dose to the unvaccinated was 0.02 at the beginning of the
22 immunization program in UK (January 2021), while the non-COVID-19 MRR of those who died 21
23 days or more after the second dose to the unvaccinated was 0.11 (95%CI: 0.08 to 0.14) for January
24 2021 and 0.13 (0.10 to 0.17) for February 2021. These indicate that healthy vaccinee effect may
25 work to lower the apparent risk of death from COVID-19 and may increase the apparent
26 effectiveness of SARS-CoV-2 vaccine. Dividing the COVID-19-related MRR of 0.02 by the
27 non-COVID-19 MRR of 0.11, yields a healthy vaccinee effect-adjusted COVID-19-related MRR of
28 0.18 (95%CI: 0.09 to 0.37). This may be considered to be closer to the true COVID-19-related
29 MRR.²⁶

30 Under similar conditions to this study, the healthy vaccinee effects estimated using UK statistics
31 are as follows. Healthy vaccinee effect by SARS-CoV-2 vaccination expressed as MRR in ever
32 vaccinated to expected mortality rate for 2021 assuming that COVID-19 is not epidemic in England
33 and Wales (932.1/100 000 person years) was estimated 0.61 in January 2021 and 0.10 to 0.24 at the
34 day of vaccination, by applying the analysis results²⁷ using data from Israeli study,⁴⁶ as shown in
35 the following another evidence.

36 The analysis results show that odds ratio (OR) of symptomatic COVID-19 on day 1 of vaccination
37 was 0.40 (95%CI: 0.31 to 0.51) and ORs of hospitalisation, severe COVID-19 and death due to
38 COVID-19 on day 1 are roughly estimated as 0.27, 0.18 and 0.13 respectively (95%CI was not

1 calculated).²⁷ Vaccination can never work at the day of vaccination; these low risk of mortality and
2 morbidity is highly probably derived from the fact that the vaccinated people were much healthier
3 than the unvaccinated. This bias could not be adjusted by ordinary methods for matching by
4 adjusting age, sex, sector, and residence, history of influenza vaccination, pregnancy and total
5 number of coexisting risk factors that Dagan et al used.

6 Theoretical basis of healthy vaccinee effect is shown by Fine et al.⁴⁸ Jackson et al⁴⁹ reported that
7 the relative risk of death, hospitalisation due to pneumonia and ischemic heart disease for influenza
8 vaccinated persons compared with unvaccinated persons was 0.36 (95%CI: 0.30 to 0.44), 0.65 (0.53
9 to 0.80) and 0.92 (0.83 to 1.02) before influenza season respectively in the United States. They
10 concluded that the reductions in risk before influenza season indicate preferential receipt of vaccine
11 by relatively healthy seniors and adjustment for diagnosis code variables did not control for this bias
12 just as in the Dagan's study.⁴⁶

13 These results indicate that the more serious the disease, the lower the apparent risk of vaccination
14 and are consistent with the results of analysis²⁷ on Dagan's data.⁴⁶

15 In fact, Husby et al¹⁶ mentioned the fact that SARS-CoV-2 vaccines are rarely given to people
16 with an acute or terminal illness as a likely explanation of low 28-day risk of cardiac arrest or death
17 in their study. This explanation is exactly the "healthy vaccinee effect".

18 Considering these, healthy vaccinee effect works in the direction of positive for vaccination (more
19 effective and safer) universally on observational studies even if many variables were matched
20 and/or adjusted by the ordinary methods used in most observational studies including propensity
21 score matching. Hence, it may be rational to take the health vaccinee effect into account in the
22 present study. Because death is a rare event, the extent of the healthy vaccinee effect on death which
23 were estimated using previously disclosed data showed wide range (0.10 to 0.24). If the least
24 healthy vaccinee effect (the highest MRR: 0.24) is used, risk of SARS-CoV-2 vaccine on
25 myocarditis death is estimated about 4 times higher than those without adjustment.

26 Lastly, this study is rather an exploratory study but not a hypothesis confirming study. However,
27 we found several strong associations especially in the age of 30s without adjustment for
28 healthy-vaccinee effect and that very high MMRR were estimated if they were adjusted for
29 healthy-vaccinee effect. Moreover, we got very high age-stratified and pooled mortality odds ratio
30 for myocarditis death. Hence, we discuss the causal inference on the increased myocarditis
31 mortality and SARS-CoV-2 vaccine use primarily according to the modified criteria of US Advisory
32 Committee to the Surgeon General⁵⁰ (modified US Surgeon General criteria) with some
33 supplementary discussion using viewpoints of causation by Hill⁵¹ (Hill's viewpoints) (Table S6).
34 Because "specificity of association" both in US Surgeon General criteria and Hill's viewpoints is an
35 extreme type of "strength of association", we included it into "strength of association" and
36 classified into 4 criteria: (1) temporarily, (2) consistency, (3) strength and (4) coherence of
37 association.

38 We found all 4 criteria were satisfied and we conclude that the association of high myocarditis

1 mortality rate ratio after SARS-CoV-2 vaccination may be causal.

2

3 **Points to be clarified in future research.**

4 Post-vaccination death should be more precisely investigated, not only from myocarditis but also
5 from other causes. These should be closely monitored by nation-wide investigation as done in
6 England and Wales or in the country with larger population. In these investigations, “healthy
7 vaccinee effect” must be taken into account.

8

9 **Conclusions and policy implications**

10 Despite above limitations, this study revealed that SARS-CoV-2 vaccination was associated with
11 higher mortality rate from myocarditis, especially in young adults compared with 2017 to 2019
12 population. But it also revealed that myocarditis death occurs in older persons. If healthy-vaccinee
13 effect is taken into account, the risk increases at least approximately 4 times more than the
14 unadjusted mortality risk. In addition, underreporting deaths after receiving vaccine should be
15 considered. Based on the results of this study, it is necessary to inform public about that the risk of
16 serious myocarditis including death may be far more serious than the risk reported before and that it
17 occurs not only in young persons but also in elderly.

1 **References**

- 2
- 3 1. SARS-CoV-2 vaccine package insert of BNT162b2 (Pfizer-BioNTech)
- 4 Available at: <https://www.fda.gov/media/151707/download> (Accessed 13 September 2022)
- 5
- 6 2. SARS-CoV-2 vaccine package insert of mRNA-1273 (Moderna).
- 7 Available at: <https://www.fda.gov/media/157233/download> (Accessed 13 September 2022)
- 8
- 9 3. Centers for Disease Control and Prevention of the United States (CDC). COVID-19 VaST Work
- 10 Group Report - May 17, 2021
- 11 Available at: <https://www.cdc.gov/vaccines/acip/work-groups-vast/report-2021-05-17.html>
- 12 (Accessed 13 September 2022)
- 13
- 14 4. Behers BJ, Patrick GA, Jones JM, et al. Myocarditis Following COVID-19 Vaccination: A
- 15 Systematic Review of Case Reports. *Yale J Biol Med* 2022; 95(2):237-47. PMID: 35782472
- 16
- 17 5. Choi S, Lee S, Seo JW, et al. Myocarditis-induced Sudden Death after BNT162b2 mRNA
- 18 COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. *J*
- 19 *Korean Med Sci* 2021; 36(40): e286. doi: 10.3346/jkms.2021.36. e286
- 20
- 21 6. Abbate A, Gavin J, Madanchi N, et al. Fulminant myocarditis and systemic hyperinflammation
- 22 temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. *Int J*
- 23 *Cardiol* 2021; 340:119-21. doi: 10.1016/j.ijcard.2021.08.018
- 24
- 25 7. Verma AK, Lavine KJ, Lin CY. Myocarditis after Covid-19 mRNA Vaccination. *N Engl J Med*
- 26 2021; 385(14):1332-34. doi: 10.1056/NEJMc2109975
- 27
- 28 8. Khogali F, Abdelrahman R. Unusual Presentation of Acute Perimyocarditis Following
- 29 SARS-COV-2 mRNA-1237 Moderna Vaccination. *Cureus* 2021; 13(7): e16590.
- 30 doi: 10.7759/cureus.16590
- 31
- 32 9. Lim Y, Kim MC, Kim KH, et al. Case Report: Acute Fulminant Myocarditis and Cardiogenic
- 33 Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal
- 34 Cardiopulmonary Resuscitation. *Front Cardiovasc Med* 2021; 8:758996.
- 35 doi: 10.3389/fcvm.2021.758996
- 36
- 37 10. Ameratunga R, Woon ST, Sheppard MN, et al. First Identified Case of Fatal Fulminant
- 38 Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA

- 1 COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity
2 Reaction. *J Clin Immunol* 2022; 42(3):441-47. doi: 10.1007/s10875-021-01187-0
3
- 4 11. Gill JR, Tashjian R, Duncanson E. Autopsy Histopathologic Cardiac Findings in 2 Adolescents
5 Following the Second COVID-19 Vaccine Dose. *Arch Pathol Lab Med* 2022; 146(8):925-29.
6 doi: 10.5858/arpa.2021-0435-SA
7
- 8 12. Hoshino N, Yanase M, Ichiyasu T, et al. An autopsy case report of fulminant myocarditis:
9 Following mRNA COVID-19 vaccination. *J Cardiol Cases* 2022
10 doi: 10.1016/j.jccase.2022.06.006
11
- 12 13. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health
13 Care Organization. *N Engl J Med* 2021; 385(23):2132-39. doi: 10.1056/NEJMoa2110737
14
- 15 14. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against
16 Covid-19 in Israel. *N Engl J Med* 2021; 385(23):2140-49. doi: 10.1056/NEJMoa2109730
17
- 18 15. Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA
19 Vaccination. *JAMA* 2021; 326(14):1390-99. doi: 10.1001/jama.2021.15072
20
- 21 16. Husby A, Hansen JV, Fosbol E, et al. SARS-CoV-2 vaccination and myocarditis or
22 myopericarditis: population based cohort study. *BMJ* 2021; 375: e068665. doi:
23 10.1136/bmj-2021-068665
24
- 25 17. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic
26 Cohort Study of 23 Million Residents. *JAMA Cardiol* 2022 doi: 10.1001/jamacardio.2022.0583
27
- 28 18. Patone M, Mei XW, Handunnetthi L, et al. Risk of Myocarditis After Sequential Doses of
29 COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. *Circulation* 2022;
30 146(10):743-54. doi:10.1161/CIRCULATIONAHA.122.059970
31
- 32 19. Japan's Prime Minister's Office. SARS-CoV-2 vaccination results by age group until 14
33 February 2022 [in Japanese]. Available at:
34 <https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html> (Accessed 18 February 2022)
35
- 36 20. Japan's Prime Minister's Office. Number of doses of SARS-CoV-2 vaccine per day by vaccine
37 type [in Japanese].
38 Available at: https://www.kantei.go.jp/jp/content/vaccination_data5.pdf

- 1 (Accessed 13 September 2022)
- 2
- 3 21. Japan's Ministry of Health, Labour and Welfare. meeting material No.1-3-1:
- 4 "The summary list of death cases after SARS-CoV-2 vaccination (Comirnaty, Pfizer) for 5
- 5 August 2022 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in
- 6 Japanese]. Available at: <https://www.mhlw.go.jp/content/10601000/000961882.pdf>
- 7 (Accessed 13 September 2022)
- 8
- 9 22. Japan's Ministry of Health, Labour and Welfare. meeting material No.1-3-2: "The summary
- 10 list of death cases after SARS-CoV-2 vaccination (Spikevax, Moderna) for 5 August 2022
- 11 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in Japanese].
- 12 Available at: <https://www.mhlw.go.jp/content/10601000/000961526.pdf>
- 13 (Accessed 13 September 2022)
- 14
- 15 23. Japan's Ministry of Health, Labour and Welfare. meeting material No.1-3-3: "The summary list
- 16 of death cases after SARS-CoV-2 vaccination (Vaxzebria, AstraZeneca)" for 5 August 2022
- 17 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in Japanese].
- 18 Available at: <https://www.mhlw.go.jp/content/10601000/000961527.pdf>
- 19 (Accessed 13 September 2022)
- 20
- 21 24. Japan's Ministry of Health, Labour and Welfare. meeting material No.2: -"On the setting of
- 22 standard for reporting suspected adverse reactions to SARS-CoV-2 vaccine" for 15 February
- 23 2022 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine, [in Japanese].
- 24 Available at: <https://www.mhlw.go.jp/content/10601000/000739053.pdf>
- 25 (Accessed 8 October 2022)
- 26
- 27 25. Joint notification by the Director of the Health Service Bureau and the Director of the
- 28 Pharmaceutical and Environmental Health Bureau, Ministry of Health, Labor and Welfare,
- 29 dated 6 December 2021 "Partial revision of "Management of the reports of the suspected
- 30 adverse reactions to routine vaccinations, etc." Available at:
- 31 <https://www.mhlw.go.jp/content/000864024.pdf> (Accessed 9 October 2022)
- 32
- 33 26. Med Check editorial team. Non-COVID-19-related deaths were reduced in the vaccinated
- 34 population Robust evidence for healthy vaccinee effect. *Med Check* 2022; 8(24): 24-31.
- 35 Available at: <https://www.npojip.org/english/MedCheck/Med%20Check%20Tip-24-2022-9-25>
- 36 (Accessed 27 September 2022)
- 37
- 38 27. Med Check editorial team. Why does vaccine look effective? Another evidence of healthy

- 1 vaccinee effect. *Med Check* 2022; 8(24): 33-37.
2 Available at: <https://www.npojip.org/english/MedCheck/Med%20Check%20Tip-24-2022-9-25>
3 (Accessed 27 September 2022)
4
- 5 28. SARS-CoV-2 vaccine package insert of ChAdOx1 nCoV-19 (Astra Zeneca).
6 Available at: [https://www.fda.gov/ph/wp-content/uploads/2021/02/PI-for-COVID-19-Vaccine-](https://www.fda.gov/ph/wp-content/uploads/2021/02/PI-for-COVID-19-Vaccine-AstraZeneca.pdf)
7 [AstraZeneca.pdf](https://www.fda.gov/ph/wp-content/uploads/2021/02/PI-for-COVID-19-Vaccine-AstraZeneca.pdf) (Accessed 13 September 2022)
8
- 9 29. Japan's Ministry of Health, Labour and Welfare. Questions and answers about vaccination
10 intervals for AstraZeneca vaccines [in Japanese]
11 Available at: <https://www.cov19-vaccine.mhlw.go.jp/qa/0090.html>
12 (Accessed 13 September 2022)
13
- 14 30. Japan's Statistics Bureau of the Ministry of Internal Affairs and Communications. Population by
15 Age (Single Year), Sex and Sex ratio - Total population, Japanese population, October 1, 2017
16 (Table 1)
17 Available at: [https://www.e-stat.go.jp/en/stat-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
18 [search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
19 [20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
20 (Accessed 13 September 2022)
21
- 22 31. Japan's Statistics Bureau of the Ministry of Internal Affairs and Communications. Population by
23 Age (Single Year), Sex and Sex ratio - Total population, Japanese population, October 1, 2018
24 (Table 1)
25 Available at: [https://www.e-stat.go.jp/en/stat-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
26 [search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
27 [20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
28 (Accessed 13 September 2022)
29
- 30 32. Japan's Statistics Bureau of the Ministry of Internal Affairs and Communications. Population by
31 Age (Single Year), Sex and Sex ratio - Total population, Japanese population, October 1, 2019
32 (Table 1)
33 Available at: [https://www.e-stat.go.jp/en/stat-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
34 [search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
35 [20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0)
36 (Accessed 13 September 2022)
37
- 38 33. Japan's Ministry of Health, Labour and Welfare. Vital Statistics, 2017, Volume 3, 1-1. Deaths by

- 1 cause (the list of three-character categories), sex and age (5-year age groups): Japan, 2017 (1)
2 ICD-10 codes A-T
3 Available at: [https://www.e-stat.go.jp/en/stat-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
4 [search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
5 [20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&re-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
6 [sult_back=1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0) (Accessed 13 September 2022)
7
8 34. Japan's Ministry of Health, Labour and Welfare. Vital Statistics, 2018, Volume 3, 1-1. Deaths by
9 cause (the list of three-character categories), sex and age (5-year age groups): Japan, 2018 (1)
10 ICD-10 codes A-T
11 Available at: [https://www.e-stat.go.jp/en/stat-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
12 [search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
13 [20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&re-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
14 [sult_back=1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0) (Accessed 13 September 2022)
15
16 35. Japan's Ministry of Health, Labour and Welfare. Vital Statistics, 2019, Volume 3, 1-1. Deaths by
17 cause (the list of three-character categories), sex and age (5-year age groups): Japan, 2019 (1)
18 ICD-10 codes A-T
19 Available at: [https://www.e-stat.go.jp/en/stat-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
20 [search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
21 [20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&re-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)
22 [sult_back=1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0) (Accessed 13 September 2022)
23
24 36. European Medicines Agency. Screening for adverse reactions in Eudra Vigilance.
25 Available at: [https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-](https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf)
26 [eudravigilance_en.pdf](https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf) (Accessed 13 September 2022)
27
28 37. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, et al. Myocarditis and pericarditis: Case
29 definition and guidelines for data collection, analysis, and presentation of immunization safety
30 data. *Vaccine* 2022; 40(10):1499-511. doi: 10.1016/j.vaccine.2021.11.074
31
32 38. Centers for Disease Control and Prevention of the United States (CDC). Reports of adverse
33 events for the SARS-CoV-2 vaccine as of 31 August 2022.
34 Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html>
35 (Accessed 13 September 2022)
36
37 39. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
38 Covid-19 Vaccine through 6 Months *N Engl J Med* 2021; 385(19):1761-73.

- 1 doi: 10.1056/NEJMoa2110345
2
- 3 40. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at
4 Completion of Blinded Phase *N Engl J Med* 2021; 385(19):1774-85.
5 doi: 10.1056/NEJMoa2113017
6
- 7 41. Hama R, Watanabe S. The risk of vaccination may be higher by considering “healthy vaccinee
8 effect”. Available at: <https://www.bmj.com/content/375/bmj-2021-068665/rr-5>
9 (Accessed 27 September 2022)
10
- 11 42. Office for National Statistics, Dataset. Deaths by vaccination status, England: Available at:
12 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datas](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsbyvaccinationstatusengland)
13 ets/deathsbyvaccinationstatusengland (Accessed 19 April 2022)
14
- 15 43. Japan’s Ministry of Health, Labour and Welfare. meeting material No.1-3-4: “The summary list
16 of death cases after SARS-CoV-2 vaccination (Comirnaty for 5 to 11 years old, Pfizer), for 5
17 August 2022 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in
18 Japanese]. Working group on adverse reactions of vaccine. Available at:
19 <https://www.mhlw.go.jp/content/10601000/000972982.pdf> (Accessed 13 September 2022)
20
- 21 44. Data on COVID-19 (coronavirus) by Our World in Data, complete COVID-19 dataset (XLSX).
22 Available at <https://github.com/owid/covid-19-data/tree/master/public/data>
23 (Accessed 2 October 2022)
24
- 25 45. National Institute of infectious diseases. Characteristics of myocarditis-related events after
26 SARS-CoV-2 vaccination reported as suspected post-vaccination adverse reaction reports from
27 medical institutions. Reported on 18 February 2022 (in Japanese) Available
28 at:<https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10984-covid19-75.html>
29 (Accessed 13 September 2022)
30
- 31 46. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
32 Vaccination Setting. *N Engl J Med* 2021; 384(15):1412-23. doi: 10.1056/NEJMoa2101765
33
- 34 47. Magen O, Waxman JG, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA Covid-19
35 Vaccine in a Nationwide Setting. *N Engl J Med* 2022; 386(17):1603-14. doi:
36 10.1056/NEJMoa2201688
37

- 1 48. Fine PEM, Chen RT. Confounding in Studies of Adverse Reactions to Vaccines. *Am J Epidemiol*
2 1992; 136(2):121-35. doi: 10.1093/oxfordjournals.aje.a116479
3
- 4 49. Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine
5 effectiveness in seniors. *Int J Epidemiol* 2006; 35(2):337-44. doi: 10.1093/ije/dyi274
6
- 7 50. US Department of Health, Education, and Welfare Public Health Service. Smoking and Health:
8 Report of the Advisory Committee to the Surgeon General of the United States. Public Health
9 Service Publication No. 1103. 1964. Available at:
10 <https://collections.nlm.nih.gov/ext/document/101584932X202/PDF/101584932X202.pdf>
11 (Accessed 02 October 2022)
12
- 13 51. Hill AB. The environment and disease: association or causation? *Proc R Soc Med* 1965; 58:
14 295-300. PMID: 14283879
15
- 16 52. Won T, Gilotra NA, Wood MK, et al. Increased Interleukin 18-Dependent Immune Responses
17 Are Associated With Myopericarditis After COVID-19 mRNA Vaccination *Front Immunol* 2022;
18 13: 851620. doi: 10.3389/fimmu.2022.851620
19
- 20 53. Decker MD, Garman PM, Hughes H, et al. Enhanced safety surveillance study of ACAM2000
21 smallpox vaccine among US military service members. *Vaccine* 2021; 39(39): 5541-47. doi:
22 10.1016/j.vaccine.2021.08.041
23

Tables

Table 1. Characteristics of included death cases after receiving SARS-CoV-2 vaccine.

Table 2. Number of persons who received vaccine by dose and person-years of exposure by age.

Table 3. Population, cause of death and mortality rate in the reference population by age.

Table 4. Myocarditis mortality rate ratios (MMRRs) by age by dose of vaccination.

Table 1 Characteristics of included death cases after receiving SARS-CoV-2 vaccine. ^{*a}

	All-cause death N (%)	Myocarditis death N (%)
Total	1 362 (100)	38 (100)
Age (years)		<i>P</i> <0.0001
12-19	7 (0.5)	0
20-29	31 (2.3)	3 (7.9)
30-39	33 (2.4)	6 (15.8)
40-49	54 (4.0)	7 (18.4)
50-59	91 (6.7)	0
60-69	124 (9.1)	4 (10.5)
70-79	302 (22.2)	8 (21.1)
80-89	453 (33.3)	8 (21.1)
≥ 90	265 (19.5)	2 (5.3)
Unknown	2 (0.1)	0
Sex		<i>P</i> =0.186
Male	750 (55.1)	25 (65.8)
Female	607 (44.6)	13 (34.2)
Unknown	5 (0.37)	0
Vaccine type		<i>P</i> <0.0001
BNT162b2 (Pfizer-BioNTech)	1 298 (95.3)	31 (81.6)
mRNA-1273 (Moderna)	63 (4.6)	7 (18.4)
ChAdOx1 nCoV-19 (Astra Zeneca)	1 (0.1)	0
Number of doses of vaccination		<i>P</i> =0.014
1	753 (55.3)	14 (36.8)
2	556 (40.8)	23 (60.5)
Unknown ^{*b}	53 (3.9)	1 (2.6)
Time from vaccination to onset of symptom		<i>P</i> =0.006
0 to 7 days	979 (71.9)	19 (50.0)
8 to 14 days	213 (15.6)	9 (23.7)
15 to 28 days	170 (12.5)	10 (26.3)
Diagnostic basis for myocarditis deaths ^{*c}		
1. Autopsy and /or myocardial biopsy		19 (50.0)
2. Elevated Troponin with blood test		3 (7.9)
3. Other blood test ^{*d} and/or (ECG and/or UCG)		12 (31.6)
4. Only symptoms		1 (2.6)
5. Unknown		3 (7.9)

***a:** Onset of symptoms leading to death occurred within 28 days after receiving the last dose of vaccine.

***b:** Dose was surely first or second but not known which dose.

***c:** Diagnostic basis for the lower number does not include the diagnostic basis for the higher number.

***d:** Possibility could not be ruled out that "Other blood tests" include elevated troponin.

Table 2| Number of persons who received vaccine by dose and person-years of exposure by age.

Age (years)	Number of persons who received			Person-years		
	A. First dose, N	B. Only first dose, N	C. Second dose, N	D. First dose, N	E. Second dose, N	F. Total N (%)
12-19	6 881 439	147 798	6 733 641	419 700	516 553	936 253 (6.8)
20-29	10 272 284	141 353	10 130 931	625 234	777 167	1 402 401 (10.3)
30-39	11 526 243	120 385	11 405 858	700 943	874 970	1 575 913 (11.5)
40-49	15 392 743	99 856	15 292 887	935 098	1 173 153	2 108 250 (15.4)
50-59	15 331 940	65 721	15 266 219	930 862	1 171 107	2 101 969 (15.4)
60-69	13 926 130	38 967	13 887 163	845 176	1 065 317	1 910 493 (14.0)
70-79	15 300 344	43 875	15 256 469	928 595	1 170 359	2 098 954 (15.4)
80-89	8 875 050	41 716	8 833 334	538 898	677 626	1 216 523 (8.9)
≥ 90	2 328 370	17 729	2 310 641	141 489	177 255	318 744 (2.3)
Total	99 834 543	717 400	99 117 143	6 065 995	7 603 507	13 669 500 (100)

$D = (A \times 22.14 + B \times 5.86) / 365$ where 22.14 was the weighted average days from first dose to second dose and 5.86 is 28 days of observation period - 22.12. $E = C \times 28 / 365$

Table 3 | Population, cause of death and mortality rate in the reference population by age.

Age (years)	Population ^{*a}	Number of deaths by cause ^{*a}		Crude mortality rate (/100,000)	
	(2017~2019)	All-cause	Myocarditis	All-cause	Myocarditis
	N (%)	N (%)	N (%)		
10-19	33 897 000 (9.7)	4 807 (0.1)	16 (3.5)	14	0.05
20-29	37 697 000 (10.8)	12 621 (0.3)	20 (4.3)	33	0.05
30-39	43 927 000 (12.6)	23 183 (0.6)	25 (5.4)	53	0.06
40-49	56 179 000 (16.1)	67 014 (1.6)	48 (10.4)	119	0.09
50-59	48 037 000 (13.8)	140 399 (1.6)	54 (11.7)	292	0.11
60-69	50 918 000 (14.6)	388 709 (3.4)	92 (19.9)	763	0.18
70-79	45 582 000 (13.1)	819 510 (9.5)	101 (21.8)	1 798	0.22
80-89	26 491 000 (7.6)	1 499 479 (20.1)	84 (18.1)	5 660	0.32
≥ 90	6 545 000 (1.9)	1 118 796 (36.8)	23 (5.0)	17 094	0.35
Total	349 273 000 (100)	4 074 518 (100)	463 (100)	1 167	0.13

*a: Population and number of deaths were all total of 3 years

Table 4| Myocarditis mortality rate ratios (MMRRs) by age by dose of vaccination.

Age (years)	First dose					Second dose					Overall				
	Ob	Ex	MMRR	95% CI		Ob	Ex	MMRR	95% CI		Ob	Ex	MMRR	95% CI	
	<i>N</i>		(SMR)	LL	UL	<i>N</i>		(SMR)	LL	UL	<i>N</i>		(SMR)	LL	UL
12-19	0	0.20	0.00	0.00	20.94	0	0.24	0.00	0.00	17.02	0	0.44	0.00	0.00	9.39
20-29	2	0.33	6.03	0.68	24.82	1	0.41	2.43	0.06	15.16	3	0.74	4.03	0.77	13.60
30-39	1	0.40	2.51	0.06	15.31	5	0.50	10.04	3.00	26.70	6	0.90	6.69	2.24	16.71
40-49	1	0.80	1.25	0.03	7.31	5	1.00	4.99	1.55	12.47	7	1.80	3.89	1.48	8.64
50-59	0	1.05	0.00	0.00	3.65	0	1.32	0.00	0.00	2.90	0	2.37	0.00	0.00	1.62
60-69	2	1.53	1.31	0.16	4.87	2	1.92	1.04	0.12	3.86	4	3.46	1.16	0.31	3.07
70-79	5	2.06	2.43	0.77	5.86	3	2.59	1.16	0.23	3.48	8	4.66	1.72	0.72	3.52
80-89	2	1.71	1.17	0.14	4.36	6	2.15	2.79	1.00	6.34	8	3.86	2.07	0.87	4.28
≥ 90	1	0.50	2.01	0.05	12.39	1	0.62	1.61	0.04	9.89	2	1.12	1.79	0.20	7.23
Total	14	8.58	1.63	0.95	2.78	23	10.75	2.21	1.45	3.37	38	19.35	2.01	1.44	2.80

Ob: Observed, Ex: Expected, LL: Lower limit, UL: Upper limit, MMRR of total was Standardized mortality ratio (SMR).

**Total death cases reported by July 22 and disclosed on 5 August 2022 : 1 797 cases
(Pfizer-BioNTech: 1 628, Moderna: 168, Astra Zeneca: 1)**

↓
→ Death cases who received vaccination after 14 Feb 2022
or who received 3rd dose or 4th dose were excluded.

**Total deaths who received 1st or 2nd dose by February 14, 2022: 1 506 cases
(Pfizer-BioNTech: 1 434, Moderna: 71, Astra Zeneca: 1)
Myocarditis deaths: 43 cases
COVID-19 deaths: 2 cases**

↓
→ Cases with onset unknown or more than 28 days
from the last dose were excluded

**Death or onset within 28 days from the last dose
(Number of deaths included in the analysis)**

Total deaths: 1 362 cases

(Death within 28 days: 1,308, Onset within 28 days: 54)

Myocarditis deaths: 38 cases

(Death within 28 days: 32, Onset within 28 days: 6)

COVID-19 deaths: 0 cases

Fig 1| Included death cases for analysis based on the list disclosed on 5 August 2022.




Fig 2| Myocarditis mortality rate ratios (MMRRs) by age and Standardised mortality ratio (SMR).